Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

About this update from Telix Pharmaceuticals Limited

MELBOURNE, Australia and INDIANAPOLIS, July 21, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides a market update on its commercial and operational performance for the quarter ended June 30, 2026 (Q2 2026). Q2 2026 Highlights[1] Q2 2026 Revenue Executive Commentary Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, "We delivered another quarter of growth with U.S. dose volumes increasing 7% during the quarter, driven by growing demand for Gozellix and continued strength across our PSMA[7] imaging portfolio. This performance underscores the strength of our differentiated two-product PSMA imaging strategy and reinforces Telix's market leadership, built on clinical differentiation, supply chain resilience and commercial execution. During the quarter, we achieved key regulatory, commercial and clinical milestones across both our Precision Medicine and Therapeutics businesses. We are tracking in line with the upper end of our FY 2026 revenue guidance and are investing further in R&D to accelerate a number of high-value programs that have the potential to create significant future growth and shareholder value." Therapeutics Business Unit Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q2 2026 highlights include: Precision Medicine Business Unit PSMA imaging portfolio: Telix's Precision Medicine business continues to expand its commercial reach and support broader patient access to PSMA-PET/CT imaging[17]. Q2 2026 highlights include: TLX101-Px, (Floretyrosine F 18 or 18F-FET) for brain cancer imaging: Zircaix®21 (TLX250-Px, 89Zr-DFO-girentuximab) for kidney cancer imaging: Telix Manufacturing Solutions (TMS): Expanded global operations TMS continues to expand its global operations which are fundamental to Telix's future growth, supporting supply chain resilience. Q2 2026 highlights include: Corporate Updates Telix entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies[26]. The strategic partnership combines Telix's radiopharmaceutical development, manufacturing and supply chain capabilities with Regeneron's leading antibody discovery and development platforms, creating a framework to advance multiple novel oncology programs and furt...

View stock analysis, news, and events for Telix Pharmaceuticals Limited